OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentCurativePolicy CHP-IP-2026-005

Atrial Fibrillation / Flutter - Acute

Customize your policy alerts

Sign up for curative Policy CHP-IP-2026-005 alerts

Get alerted when Policy CHP-IP-2026-005 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs emergency department discharge, observation, acute inpatient admission, level-of-care assignment, continued stay, discharge readiness, and monitored initiation of selected antiarrhythmic drugs for adults with acute atrial fibrillation or atrial flutter. It applies to Curative commercial PPO and EPO members in fully insured, level-funded, and self-funded plans.

Policy Summary

PayerCurative

PolicyAtrial Fibrillation / Flutter - Acute

Policy CodePolicy CHP-IP-2026-005

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionDocument at least one qualifying clinical severity finding and one required hospital-level service for acute inpatient admission.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Adults 18+Applicable population

3 days minimumDofetilide monitoring

<110 bpmResting rate target

4 weeksPost-cardioversion anticoagulation

24 hoursContinued-stay review

Medical Necessity and Level-of-Care Criteria

Inpatient admission versus observation or discharge

Covered when ALL of the following are met:

Inpatient admission

Clinical severity finding
- Hemodynamic compromise: Systolic blood pressure below 90 mm Hg, altered mental status, ischemic chest pain, or acute pulmonary edema attributable to the arrhythmia.SBP <90 mm Hg
- Refractory ventricular rate: Resting ventricular rate remains above 110 beats per minute despite at least 2 appropriately dosed intravenous rate-control doses in the emergency department, requiring continuous infusion.>110 bpm after at least 2 IV doses

Policy Summary

PayerCurative

PolicyAtrial Fibrillation / Flutter - Acute

Policy CodePolicy CHP-IP-2026-005

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionDocument at least one qualifying clinical severity finding and one required hospital-level service for acute inpatient admission.

SourceLink

On This Page

Pre-excited AF: Irregular wide-complex tachycardia with accessory-pathway conduction.

Tachycardia-bradycardia syndrome: Symptomatic bradycardia or pauses longer than 3 seconds requiring monitoring or temporary pacing.pause >3 seconds

Concurrent inpatient condition: Acute coronary syndrome, acute heart failure, pulmonary embolism, sepsis, thyrotoxicosis, or significant bleeding on anticoagulation requiring inpatient care.

Tachycardia-mediated cardiomyopathy: Suspected tachycardia-mediated cardiomyopathy with new left ventricular dysfunction and heart failure symptoms.

Hospital-level service

Continuous infusion: Continuous intravenous diltiazem or esmolol rate-control infusion, or intravenous amiodarone with frequent titration.
Urgent cardioversion: Urgent synchronized cardioversion with sedation and post-procedure monitoring when the member is unstable or has a concurrent inpatient condition.
Monitored antiarrhythmic initiation: Initiation of dofetilide with a minimum of 3 days of continuous ECG monitoring, or oral sotalol when the label requires monitored initiation.dofetilide >=3 days
Pacing or pacemaker evaluation: Temporary pacing or urgent permanent pacemaker evaluation for tachycardia-bradycardia syndrome.
Concurrent condition treatment: Treatment of the concurrent inpatient condition.

Intensive care unit

Covered when ANY of the following ICU criteria are met:

ICU level of care

Shock or repeated cardioversion: Persistent hypotension or shock requiring vasopressors or repeated cardioversion.
Severe pre-excited AF: Pre-excited AF with hemodynamic compromise or ventricular rate above 250 beats per minute.>250 bpm
Pulmonary edema with ventilation: AF with acute pulmonary edema requiring noninvasive or invasive ventilation.
Concurrent critical illness, such as septic shock, is the primary ICU indication.

Step-down or intermediate care

Covered when no ICU criterion is met and ANY of the following applies:

Continuous infusion: Continuous intravenous diltiazem, esmolol, or amiodarone infusion.
Monitored antiarrhythmic loading: Dofetilide or sotalol initiation with QTc monitoring after each dose.
Post-cardioversion monitoring in a member with structural heart disease or pauses.
Tachycardia-bradycardia syndrome awaiting pacing.

Medical-surgical level of care

Medical-surgical care is appropriate when continued acute care is needed but no ICU or step-down criterion is met:

Medical-surgical unit

Transition to oral rate control: Transition from intravenous to oral rate control within the previous 12–24 hours.12–24 hours
Precipitating condition: Treatment of a precipitating condition requiring inpatient care at the medical-surgical level.

Discharge readiness

Covered for discharge readiness when ALL of the following are met:

Rate or rhythm controlled: Resting heart rate is below 110 beats per minute on oral therapy, or sinus rhythm is maintained after cardioversion.HR <110 bpm
Infusions discontinued: Off intravenous rate-control or antiarrhythmic infusions for at least 12 hours.>=12 hours
Stable blood pressure: Systolic blood pressure is at least 100 mm Hg without symptoms at rest.SBP >=100 mm Hg
Stroke prevention plan: Stroke-risk score is documented and anticoagulation is started, or the reason for not anticoagulating is documented; after cardioversion, anticoagulation is continued for at least 4 weeks.>=4 weeks after cardioversion
Antiarrhythmic loading completed: If dofetilide or sotalol was started, required monitored doses are completed, QTc is acceptable per label, and renal dosing is confirmed.Dofetilide QTc <500 ms or <550 ms with conduction abnormality
Precipitating condition addressed: The precipitating condition is addressed, such as thyroid function checked, infection treated, or alcohol use counseled.
Follow-up and education: Cardiology or electrophysiology follow-up is arranged within 1–2 weeks, with education on pulse checks, bleeding, and warning symptoms.1–2 weeks

Continued stay

Continued inpatient stay is medically necessary when ANY of the following is documented; review every 24 hours:

Continued-stay criteria

Uncontrolled rate: Ventricular rate is not controlled on oral agents and intravenous infusion is still required.
Dofetilide or sotalol loading: Dofetilide loading is in progress for a minimum of 3 days, or sotalol loading requires monitoring.Dofetilide >=3 days
Recurrent AF after cardioversion requires an additional in-hospital intervention.
Concurrent condition: A concurrent condition still requires inpatient management.
Pacemaker pending: Pacemaker implantation is pending for symptomatic tachycardia-bradycardia syndrome.

Does not meet criteria

The following scenarios do not meet medical-necessity criteria and require physician review:

Stable controlled-rate admission: Admission of a stable member whose rate is controlled after initial emergency department therapy and who has no concurrent inpatient condition.
Emergency department discharge or observation is appropriate.
Admission solely for anticoagulant initiation: Admission solely to start a direct oral anticoagulant.
Direct oral anticoagulants are started as outpatients.
Elective cardioversion only: Admission solely for elective cardioversion in a stable, anticoagulated member.
Outpatient or short observation procedure.
Outpatient-appropriate testing: Continued stay solely to await outpatient-appropriate testing, such as an echocardiogram or sleep study.
Wrong site of care.
Awaiting placement: Days awaiting placement after discharge-readiness criteria are met without an acute need.
Custodial days do not meet acute criteria; refer for physician review and discharge planning.

This policy applies to acute atrial fibrillation or flutter. Atrial fibrillation managed as a complication of another admission is reviewed under the policy governing that admission. Elective catheter ablation and left atrial appendage occlusion are governed by their applicable procedure policies, and atrial fibrillation with acute stroke is governed by the stroke policy.

The following scenarios do not meet acute inpatient medical-necessity criteria: admission of a stable member whose rate is controlled after initial emergency department treatment and who has no concurrent inpatient condition; admission solely to start a direct oral anticoagulant; admission solely for elective cardioversion in a stable, anticoagulated member; continued stay solely to await outpatient-appropriate testing; or days awaiting placement after discharge-readiness criteria are met without an acute need. These requests require physician review rather than automated or non-physician denial.

Coding and Operational Definitions

Revenue codesRevenue

0120	Revenue code 0120
0210	Revenue code 0210
0250	Revenue code 0250
0300	Revenue code 0300
0481	Revenue code 0481
0730	Revenue code 0730

ICD-10-CM: atrial fibrillation and flutterICD-10

I48.0	Atrial fibrillation and flutter
I48.11	Atrial fibrillation and flutter
I48.19	Atrial fibrillation and flutter
I48.20	Atrial fibrillation and flutter
I48.21	Atrial fibrillation and flutter
I48.3	Atrial fibrillation and flutter
I48.4	Atrial fibrillation and flutter
I48.91	Atrial fibrillation and flutter
I48.92	Atrial fibrillation and flutter

ICD-10-PCS: external cardioversionICD-10

5A2204Z

External cardioversion

MS-DRG: cardiac arrhythmia and conduction disordersmixed

308	Cardiac arrhythmia and conduction disorders
309	Cardiac arrhythmia and conduction disorders
310	Cardiac arrhythmia and conduction disorders

Rapid ventricular response

DefinitionAF or flutter with a resting ventricular rate above 110 beats per minute.

Admission relevanceA persistently elevated resting ventricular rate may support inpatient admission when it remains above 110 beats per minute despite at least 2 appropriately dosed intravenous rate-control doses.

Controlled-rate thresholdA resting heart rate below 110 beats per minute is the controlled-rate threshold used for observation, discharge, and lenient rate control.

Refractory rate for admission

Rate thresholdResting ventricular rate persistently above 110 beats per minute.

Treatment requirementThe rate remains elevated despite at least 2 appropriately dosed intravenous rate-control doses in the emergency department.

Additional requirementContinuous intravenous rate-control infusion is required.

Controlled rate

Heart-rate thresholdResting heart rate below 110 beats per minute.

Observation or dischargeAfter 1–2 intravenous or oral doses, a rate below 110 beats per minute may support emergency department discharge when the member is hemodynamically stable, has no concurrent inpatient condition, and has follow-up arranged.

Discharge therapyFor discharge, the rate must remain below 110 beats per minute on oral therapy, or sinus rhythm must be maintained after cardioversion.

Recent-onset AF

Recent onsetAtrial fibrillation present for less than 48 hours.

Anticoagulation alternativeAlternatively, the member has been on therapeutic anticoagulation for at least 3 weeks.

Care settingA stable member meeting either condition may be suitable for emergency department or observation cardioversion.

Dofetilide monitoring

Monitoring durationMinimum 3 days of continuous ECG monitoring.

Facility capabilitiesThe facility must be able to calculate creatinine clearance, provide continuous electrocardiographic monitoring, and provide cardiac resuscitation.

ApplicabilityThe requirement applies to dofetilide initiation or re-initiation.

Tachycardia-bradycardia pause

Pause thresholdPauses longer than 3 seconds.

Clinical syndromeThe finding is associated with tachycardia-bradycardia syndrome.

Admission relevanceSymptomatic bradycardia or pauses longer than 3 seconds support inpatient care when monitoring or temporary pacing is required.

Intravenous therapy-free period

Required intervalAt least 12 hours without intravenous rate-control or antiarrhythmic infusions.

Discharge applicationThe member must be off intravenous rate-control or antiarrhythmic infusions for at least 12 hours before discharge.

DocumentationDischarge documentation should confirm discontinuation of intravenous infusions for at least 12 hours.

Discharge blood pressure

Systolic pressureAt least 100 mm Hg.

Symptom requirementNo symptoms at rest.

Discharge applicationBoth the blood-pressure threshold and absence of resting symptoms are required for discharge readiness.

QTc safety threshold

Standard QTc thresholdBelow 500 ms.

Conduction abnormality thresholdBelow 550 ms with a ventricular conduction abnormality.

Safety actionQTc above 500 ms, or above 550 ms with conduction delay, is a red flag during antiarrhythmic loading and requires stopping or reducing the drug per label and escalating monitoring.

Post-cardioversion anticoagulation

Minimum durationAt least 4 weeks after cardioversion.

Discharge requirementAfter cardioversion, anticoagulation must continue for at least 4 weeks.

Clinical basisThe cited atrial-fibrillation guideline supports at least 4 weeks of anticoagulation after cardioversion.

Expected stay

Uncomplicated AF with rapid ventricular responseAbout 1–2 days.

Dofetilide initiationAt least 3 days.

Use of estimateExpected length of stay is a planning benchmark only and does not limit covered days.

Documentation, Authorization, and Review Actions

Prior Authorization

Inpatient Admission Requires Severity and Hospital Service

Inpatient admission for acute AF or atrial flutter requires both at least one qualifying clinical severity finding and at least one required hospital-level service. Document the specific finding and service supporting admission.

Severity findings may include hemodynamic compromise, persistent ventricular rate above 110 despite appropriately dosed IV therapy requiring continuous infusion, pre-excited AF, symptomatic bradycardia or pauses, a concurrent inpatient condition, or suspected tachycardia-mediated cardiomyopathy.
Hospital-level services may include continuous IV rate-control or IV amiodarone infusion, urgent synchronized cardioversion with monitoring, monitored dofetilide or sotalol initiation, temporary pacing or urgent pacemaker evaluation, or treatment of the concurrent inpatient condition.

Prior Authorization

Match Authorization to Level of Care

Match the requested authorization to the documented level-of-care criteria. Request ICU, step-down/intermediate, or medical-surgical care only when the member's active needs support that setting.

ICU: persistent hypotension or shock requiring vasopressors or repeated cardioversion, hemodynamically compromising pre-excited AF or ventricular rate above 250, acute pulmonary edema requiring ventilation, or another concurrent critical illness.
Step-down/intermediate: continuous IV diltiazem, esmolol, or amiodarone; monitored dofetilide or sotalol initiation; post-cardioversion monitoring with structural heart disease or pauses; or tachycardia-bradycardia syndrome awaiting pacing.
Medical-surgical: continued acute care without ICU or step-down criteria, such as recent transition from IV to oral rate control or treatment of a precipitating condition requiring inpatient care.

Unsupported block type: documentation

Unsupported block type: prior_auth

Documentation Required

Required Clinical Documentation

Include sufficient clinical evidence to establish the diagnosis, severity, treatment response, level of care, and discharge plan. The record should contain the requested ECG, rate, QTc, hemodynamic, and related clinical information.

ECG confirming AF or flutter and ventricular rate; QTc during antiarrhythmic loading.
Hemodynamics and response to emergency-department treatment.
Onset or duration, anticoagulation status before cardioversion, CHA2DS2-VASc score, and bleeding-risk assessment.
Evaluation of precipitating causes, including thyroid disease, infection, ischemia, pulmonary embolism, and alcohol; echocardiogram when new AF or heart failure is present.
Discharge rate or rhythm plan, anticoagulation plan, and follow-up.

Documentation Required

Discharge Readiness Documentation

Document that all discharge-readiness elements are satisfied before discharge. The member should be clinically stable on the planned outpatient regimen and have a documented anticoagulation, follow-up, and education plan.

Resting heart rate below 110 on oral therapy or maintained sinus rhythm after cardioversion.
No IV rate-control or antiarrhythmic infusion for at least 12 hours and systolic blood pressure at least 100 mm Hg without symptoms at rest.
Stroke-risk score and anticoagulation decision documented; after cardioversion, continue anticoagulation for at least 4 weeks.
If dofetilide or sotalol was started, complete monitored doses, confirm acceptable QTc and renal dosing.
Address precipitating conditions and document cardiology/electrophysiology follow-up within 1–2 weeks plus education on pulse checks, bleeding, and warning symptoms.

Unsupported block type: documentation

Billing Rule

Support Requested Quantity and Duration

The requested quantity, units, and duration must be supported by the submitted documentation. Expected length of stay and DRG geometric mean values are planning benchmarks only and do not establish an automatic coverage limit.

Uncomplicated AF with rapid ventricular response commonly has an expected stay of about 1–2 days; dofetilide initiation requires at least 3 days.
Explain extended duration when rate remains refractory to oral therapy, antiarrhythmic loading continues, repeat cardioversion is required, pacemaker implantation is pending, IV therapy is needed for heart failure, or bleeding complications require care.

Unsupported block type: denial_risk

Denial Risk

Red Flags Requiring Escalation

Immediately escalate findings that indicate instability, serious complications, or antiarrhythmic safety risk. These findings may change the review pathway and require urgent treatment before routine progression or discharge.

Hypotension, ischemic chest pain, pulmonary edema, or altered mentation with AF: urgent cardioversion and ICU-level care may be required.
Irregular wide-complex tachycardia suggesting pre-excitation: avoid AV-nodal blockers and obtain urgent cardioversion or appropriate antiarrhythmic and electrophysiology consultation.
QTc above 500 ms (or above 550 ms with conduction delay), torsades de pointes, or a new ventricular arrhythmia during loading: stop or reduce therapy per label and escalate monitoring.
New focal neurologic deficit, major bleeding on anticoagulation, or uncontrolled rate/hemodynamic symptoms at planned discharge require urgent evaluation; discharge may be unsafe.

Unsupported block type: prior_auth

Unsupported block type: denial_risk

Unsupported block type: billing_rule

Unsupported block type: denial_risk

Unsupported block type: billing_rule

Clinical Background

Acute atrial fibrillation or flutter may be managed with rate control, rhythm control, cardioversion, anticoagulation, and treatment of precipitating conditions. Stroke-risk assessment guides anticoagulation decisions, while the choice of rate or rhythm control is individualized to symptoms. Most patients with rapid ventricular response who stabilize after initial treatment can be discharged from the emergency department or observed briefly; inpatient care is generally reserved for hemodynamic compromise, refractory rates, pre-excitation, serious concurrent illness, or medications requiring monitored initiation. Dofetilide initiation requires continuous ECG monitoring in a facility for at least 3 days.

Key Definitions

Rapid ventricular response

DefinitionAF or flutter with a resting ventricular rate above 110 beats per minute.

Admission thresholdFor refractory rate, the resting ventricular rate remains above 110 beats per minute despite at least 2 appropriately dosed intravenous rate-control doses.

Care implicationA controlled resting heart rate is below 110 beats per minute.

Pre-excited AF

DefinitionAF conducted over an accessory pathway, producing an irregular wide-complex tachycardia.

Contraindicated treatmentAtrioventricular nodal blockers are contraindicated.

Urgent managementPre-excited AF with hemodynamic compromise or a ventricular rate above 250 beats per minute supports ICU care; an irregular wide-complex tachycardia requires avoidance of atrioventricular nodal blockers and urgent clinical management.

CHA2DS2-VASc

PurposeCHA2DS2-VASc is a validated stroke-risk score used to guide anticoagulation in atrial fibrillation.

MenAnticoagulation is recommended at a score of 2 or more in men.

WomenAnticoagulation is recommended at a score of 3 or more in women.

Lenient rate control

Rate targetResting heart rate below 110 beats per minute.

Symptom conditionThe target is acceptable when symptoms are controlled.

Cardiac-function conditionThe target is acceptable when ventricular function is preserved.

CHA2DS2-VASc

DefinitionA validated atrial-fibrillation stroke-risk prediction score.

Clinical useIt is used to determine anticoagulation thresholds.

Guideline roleThe score is used in the guideline thresholds for anticoagulation decisions.

Monitored antiarrhythmic initiation

TreatmentFacility-based dofetilide initiation or re-initiation.

Minimum monitoring periodAt least 3 days with continuous ECG monitoring.

Required capabilitiesThe facility must calculate creatinine clearance and provide cardiac-resuscitation capability.